Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Alembic receives EIR from USFDA for facility at Panelav
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Subscribe To Our Newsletter & Stay Updated